gefitinib has been researched along with lovastatin in 14 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (lovastatin) | Trials (lovastatin) | Recent Studies (post-2010) (lovastatin) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 4,828 | 698 | 873 |
| Protein | Taxonomy | gefitinib (IC50) | lovastatin (IC50) |
|---|---|---|---|
| Chain A, Antigen Cd11a (p180) | Homo sapiens (human) | 2.4 | |
| 3-hydroxy-3-methylglutaryl-coenzyme A reductase | Homo sapiens (human) | 0.0261 | |
| Integrin beta-2 | Homo sapiens (human) | 3.09 | |
| Intercellular adhesion molecule 1 | Homo sapiens (human) | 3.78 | |
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | 8.753 | |
| ATP-dependent translocase ABCB1 | Homo sapiens (human) | 10 | |
| Neutrophil elastase | Homo sapiens (human) | 0.027 | |
| Insulin receptor | Rattus norvegicus (Norway rat) | 0.02 | |
| Integrin alpha-L | Homo sapiens (human) | 3.09 | |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 8.753 | |
| Prostaglandin G/H synthase 2 | Homo sapiens (human) | 0.02 | |
| 3-hydroxy-3-methylglutaryl-coenzyme A reductase | Rattus norvegicus (Norway rat) | 0.0529 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (28.57) | 29.6817 |
| 2010's | 10 (71.43) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Aleo, MD; Bonin, PD; Luo, Y; Potter, DM; Swiss, R; Will, Y | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Dimitroulakos, J; Goss, G; Hanson, JE; Lagarde, AE; Lorimer, IA; Mantha, AJ | 1 |
| Barrett, GM; Cemeus, C; Dimitroulakos, J; Lorimer, IA; Zhao, TT | 1 |
| Han, JY; Jung, JI; Kim, JY; Park, IH | 1 |
| Addison, CL; Dimitroulakos, J; Trinh, D; Zhao, TT | 1 |
| Boerner, JL; Bohin, N; Ge, Y; Irwin, ME; Mueller, KL | 1 |
| Dayekh, K; Dimitroulakos, J; Gorn-Hondermann, I; Ma, L; Niknejad, N | 1 |
| Chang, VH; Chen, CC; Jiang, X; Lin, HY; Liu, YR; Wang, J; Yang, SH; Yen, Y; Zhang, K | 1 |
1 review(s) available for gefitinib and lovastatin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
13 other study(ies) available for gefitinib and lovastatin
| Article | Year |
|---|---|
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Chemical and Drug Induced Liver Injury; Humans; Male; Mitochondria, Liver; Rats; Rats, Sprague-Dawley; Severity of Illness Index | 2014 |
Targeting the mevalonate pathway inhibits the function of the epidermal growth factor receptor.
Topics: Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Binding Sites; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Colonic Neoplasms; Drug Synergism; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Lovastatin; Lung Neoplasms; Mevalonic Acid; Mitogen-Activated Protein Kinases; Mutation; Phosphorylation; Quinazolines; Signal Transduction; Tumor Cells, Cultured | 2005 |
Lovastatin enhances gefitinib activity in glioblastoma cells irrespective of EGFRvIII and PTEN status.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Flow Cytometry; Gefitinib; Glioblastoma; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; PTEN Phosphohydrolase; Quinazolines | 2008 |
Lovastatin overcomes gefitinib resistance in human non-small cell lung cancer cells with K-Ras mutations.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Gefitinib; Humans; Lovastatin; Lung Neoplasms; Mutation; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Signal Transduction | 2010 |
Lovastatin inhibits VEGFR and AKT activation: synergistic cytotoxicity in combination with VEGFR inhibitors.
Topics: Cell Line, Tumor; Cell Survival; Down-Regulation; Drug Synergism; Gefitinib; Humans; Lovastatin; Proto-Oncogene Proteins c-akt; Quinazolines; Transcriptional Activation; Vascular Endothelial Growth Factor Receptor-2 | 2010 |
Lipid raft localization of EGFR alters the response of cancer cells to the EGFR tyrosine kinase inhibitor gefitinib.
Topics: Atorvastatin; Benzylamines; beta-Cyclodextrins; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cholesterol; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; ErbB Receptors; Female; Gefitinib; Heptanoic Acids; Humans; Lovastatin; Membrane Microdomains; Phosphorylation; Protein Kinase Inhibitors; Protein Transport; Proto-Oncogene Proteins c-akt; Pyrroles; Quinazolines; Thiophenes | 2011 |
Lovastatin induces multiple stress pathways including LKB1/AMPK activation that regulate its cytotoxic effects in squamous cell carcinoma cells.
Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Line; Cell Line, Tumor; Drug Synergism; Fibroblasts; Gefitinib; Gene Deletion; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Lovastatin; Metformin; Mice; Protein Serine-Threonine Kinases; Quinazolines; Signal Transduction | 2012 |
Lovastatin overcomes gefitinib resistance through TNF-α signaling in human cholangiocarcinomas with different LKB1 statuses in vitro and in vivo.
Topics: AMP-Activated Protein Kinase Kinases; Animals; Antineoplastic Agents; Apoptosis; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Carcinoma, Non-Small-Cell Lung; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cholangiocarcinoma; Drug Resistance, Neoplasm; Drug Synergism; Gefitinib; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Lung Neoplasms; Male; Mice; Mice, Inbred ICR; Protein Serine-Threonine Kinases; Quinazolines; RNA Interference; RNA, Small Interfering; Signal Transduction; Tumor Necrosis Factor-alpha; Xenograft Model Antitumor Assays | 2015 |